Abstract
Community perception of the safety of vaccines in the interest of public health influences vaccine uptake. Challenges for active vaccine safety monitoring include survey response rates, unbiased reporting and the balance between specificity and sensitivity of signal detection methods. To address these problems, we used causal DAGs and statistical methods to guide understanding of biological and behavioural factors which may influence vaccine safety signal detection. The DAGs informed the generation of scenarios in which these factors were varied. A posterior predictive analysis (PPA) signal detection method, based upon a Bayesian logistic model, was used to detect signals across the scenarios. In the high probability of severe reaction scenarios, true signals were generated where there was higher survey participation with more survey responder AEFI data available for analysis. In the low probability of severe reaction scenarios, false signals were generated when there was a strong influence of reaction severity on survey participation and reports of severe reactions. Low rates of survey participation reduce the amount of data available to inform the parameters of the statistical model, and therefore reduce the certainty regarding the value of these parameters. We obtained insights into the value of the causal DAG to account for survey non-response, to guide understanding of short-term vaccine safety, interpret the results of the PPA analysis under plausible scenarios, and review implications for future vaccine safety monitoring
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project is supported by the Australian Government Department of Health and Aged Care via the AusVaxSafety programme.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data simulation code is available on Github. See link below and also within the manuscript